In the pipeline from Derek Lowe – Page 2
-
OpinionThe psychology of our future with AI
It’s time to accept that digitalisation is changing laboratory work, and embrace the opportunity
-
OpinionSetting drug development speed records
The pandemic treatment sprint was spectacular, but hard to match under less unusual circumstances
-
OpinionEmbracing oddities
When new chemistry looks like alchemy or witchcraft, it’s worth taking notice
-
OpinionNobel vision
Looking beyond the here-and-now let click chemistry open up a whole new world of possibility
-
OpinionDo science courses need hands-on labs to be effective?
The practical lab is where abstract theory connects to physical reality
-
OpinionWhy AlphaFold won’t revolutionise drug discovery
Protein structure prediction is a hard problem, but even harder ones remain
-
OpinionMay cause side effects
The dose makes the poison, but understanding unwanted drug interactions is complicated
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
OpinionCatalogues of complexity
The tangled web of fine chemicals supply frequently throws up surprises
-
OpinionExit strategy
Overcoming a major setback showed Derek Lowe could make it through graduate school
-
OpinionA spanner in the works
Most drugs work by breaking or stopping something, rather than by making something faster or better
-
OpinionScents and sentimentality
Deprived of familiar lab odours, Derek Lowe indulges in some nasal nostalgia
-
OpinionThe law of conservation of data
AI and machine learning are useful and powerful, but they need high quality data inputs that aren’t available yet for drug discovery
-
OpinionReverse combustion is preparing for takeoff
Where burning hydrocarbons is unavoidable, creating them from atmospheric carbon is a promising option
-
OpinionAll work and no play
Is the long-hours culture of academic organic chemistry laboratories finally changing?
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
OpinionThe price of failure
Drug market structures and high R&D failure rates can tempt companies into bad pricing behaviour
-
OpinionPutting combustion into reverse
Unburning carbon dioxide economically and at scale is a tough problem, but potentially world-changing
-
OpinionOpening up a cellular black box
Working out how biomolecular condensates work may reveal a lot about the success or failure of different drugs
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance